Dr Feliu and colleagues from Spain investigated the efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer in an open, multicenter, uncontrolled study.
The patients were considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination.
Treatment consisted of capecitabine 1250 mg m−2 twice daily on days 1–14 and bevacizumab on day 1 every 3 weeks.
A total of 59 patients aged greater than or equal to 70 years with metastatic colorectal cancer were enrolled.
|The overall response rate was 34%|
|British Journal of Cancer|
In an intention-to-treat analysis, the overall response rate was 34%, with 71% of patients achieving disease control.
Median progression-free survival and overall survival were 11 months and 18 months, respectively.
In all, 32 patients had grade 3/4 adverse events, the most common being hand–foot syndrome, diarrhoea and deep venous thrombosis.
The researchers noted that 4 patients died because of treatment-related adverse events.
The research team detected a relationship between creatinine clearance less than or equal to 50ml per minute and the development of non-bevacizumab-related grade 3/4 adverse events.
The team observed that the incidence of bevacizumab-associated adverse events was consistent with that of previous reports in elderly patients.
Dr Feliu's team concluded, "Bevacizumab combined with capecitabine represents a valid therapeutic alternative in elderly patients considered to be unsuitable for receiving polychemotherapy."